| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Journal of Applied Physiology, Vol 65, Issue 5 1975-1983, Copyright © 1988 by American Physiological Society
ARTICLES |
S. Adnot, P. E. Chabrier, C. Brun-Buisson, I. Viossat and P. Braquet
Unite de Recherches de Physiologie Respiratoire Institut National de la Sante et de la Recherche Medicale, Creteil, France.
The influence of endogenous and exogenous atrial natriuretic factor (ANF) on pulmonary hemodynamics was investigated in anesthetized pigs during both normoxia and hypoxia. Continuous hypoxic ventilation with 11% O2 was associated with a uniform but transient increase of plasma immunoreactive (ir) ANF that peaked at 15 min. Plasma irANF was inversely related to pulmonary arterial pressure (Ppa; r = -0.66, P less than 0.01) and pulmonary vascular resistance (PVR; r = -0.56, P less than 0.05) at 30 min of hypoxia in 14 animals; no such relationship was found during normoxia. ANF infusion after 60 min of hypoxia in seven pigs reduced the 156 +/- 20% increase in PVR to 124 +/- 18% (P less than 0.01) at 0.01 microgram.kg-1.min-1 and to 101 +/- 15% (P less than 0.001) at 0.05 microgram.kg-1.min-1. Cardiac output (CO) and systemic arterial pressure (Psa) remained unchanged, whereas mean Ppa decreased from 25.5 +/- 1.5 to 20.5 +/- 15 mmHg (P less than 0.001) and plasma irANF increased two- to nine-fold. ANF infused at 0.1 microgram.kg-1.min-1 (resulting in a 50-fold plasma irANF increase) decreased Psa (-14%) and reduced CO (-10%); systemic vascular resistance (SVR) was not changed, nor was a further decrease in PVR induced. No change in PVR or SVR occurred in normoxic animals at any ANF infusion rate. These results suggest that ANF may act as an endogenous pulmonary vasodilator that could modulate the pulmonary pressor response to hypoxia.
This article has been cited by other articles:
|
|
 |
|
  L. B. Yap, D. Mukerjee, P. M. Timms, H. Ashrafian, and J. G. Coghlan Natriuretic Peptides, Respiratory Disease, and the Right Heart Chest, October 1, 2004; 126(4): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakanishi, H. Osada, M. Uenoyama, F. Kanazawa, N. Ohrui, Y. Masaki, T. Hayashi, Y. Kanatani, T. Ikeda, and T. Kawai Expressions of adrenomedullin mRNA and protein in rats with hypobaric hypoxia-induced pulmonary hypertension Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2159 - H2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Klinger, R. R. Warburton, L. Pietras, P. Oliver, J. Fox, O. Smithies, and N. S. Hill Targeted disruption of the gene for natriuretic peptide receptor-A worsens hypoxia-induced cardiac hypertrophy Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H58 - H65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Klinger, L. Pietras, R. Warburton, and N. S. Hill Reduced Oxygen Tension Increases Atrial Natriuretic Peptide Release from Atrial Cardiocytes Experimental Biology and Medicine, October 1, 2001; 226(9): 847 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Schermuly, N. Weissmann, B. Enke, H. A. Ghofrani, W. G. Forssmann, F. Grimminger, W. Seeger, and D. Walmrath Urodilatin, a Natriuretic Peptide Stimulating Particulate Guanylate Cyclase, and the Phosphodiesterase 5 Inhibitor Dipyridamole Attenuate Experimental Pulmonary Hypertension . Synergism upon Coapplication Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hampl and J. Herget Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension Physiol Rev, October 1, 2000; 80(4): 1337 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Klinger, R. R. Warburton, L. A. Pietras, O. Smithies, R. Swift, and N. S. Hill Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice Am J Physiol Lung Cell Mol Physiol, May 1, 1999; 276(5): L868 - L874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Klinger, F. M. Siddiq, R. A. Swift, C. Jackson, L. Pietras, R. R. Warburton, C. Alia, and N. S. Hill C-type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats Am J Physiol Lung Cell Mol Physiol, October 1, 1998; 275(4): L645 - L652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Klinger, R. R. Warburton, L. Pietras, and N. S. Hill Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats J Appl Physiol, May 1, 1998; 84(5): 1646 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. FISCHER, D. J. DEYO, H. G. BONE, R. MCGUIRE, L. D. TRABER, and D. L. TRABER Nitric Oxide Synthase Inhibition Restores Hypoxic Pulmonary Vasoconstriction in Sepsis Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 833 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. E. Albert, V. L. Tucker, and E. M. Renkin Atrial natriuretic peptide levels and plasma volume contraction in acute alveolar hypoxia J Appl Physiol, January 1, 1997; 82(1): 102 - 110. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
